Gene Panel Market Size & Share Analysis - Growth Trends and Forecast (2026 - 2031)

Global Gene Panel Market Trends and Insights

Accelerating Oncology-Focused Clinical Adoption Through NGS Reimbursement Expansion

Expanded payer coverage transforms oncology testing economics and speeds the shift from sequential single-gene assays to comprehensive panels. CMS Local Coverage Determination L37810 now covers advanced solid tumors, while Blue Cross Blue Shield networks codify medical-necessity criteria such as pre-test counseling and relevant family histories. Value-based care reimbursement aligns with upfront genomic profiling because early molecular stratification reduces downstream chemotherapy failures. Community oncology practices adopt panel testing as standard of care, shortening diagnostic odysseys and boosting targeted-therapy utilization. Laboratories leverage this demand spike by bundling tissue and blood-based assays, thereby enlarging the total order value per patient. The resulting volume gains reinforce economies of scale and lower the unit cost curve across the gene panel market.

AI-Powered Interpretation Tools Slashing VUS Rates and Turnaround Times

Artificial-intelligence engines digest millions of prior case variants and real-world outcomes, converting raw NGS data into concise clinical reports within hours. Invitae’s Clinical Variant Modeling lowered variants of uncertain significance by 24% for Lynch syndrome genes across 4 million samples ^{[2]Invitae Corp., “Clinical Variant Modeling: Reducing Uncertainty in Genetic Testing,” invitae.com} . QIAGEN’s QCI Interpret now handles 850,000 cases annually, delivering batch-level interpretation for high-throughput laboratories ^{[3]QIAGEN N.V., “QCI Interpret Powers High-Throughput Clinical NGS,” qiagen.com} . Early deployments show 30-50% reductions in report-generation labor and meaningful acceleration of patient management decisions. Academic consortia such as AI-MARRVEL demonstrate 98% precision in rare-disease variant classification, doubling diagnostic yields over traditional curation workflows. As AI models continue to learn from federated clinical repositories, algorithmic interpretation becomes a must-have differentiator across the gene panel market.

Increasing Prevalence of Multi-Gene Pharmacogenomic Labels in FDA Approvals

FDA labels referencing CPIC or PharmGKB pharmacogenomic guidance jumped sharply during 2024–2025 drug approvals, spanning cardiovascular, psychiatric, and oncology classes. The PREPARE study under the Department of Veterans Affairs showed a 30% cut in adverse drug reactions using a 12-gene panel before prescription. Medicare’s draft Local Coverage Determination requires panels to demonstrate actionability per CPIC tables, cementing coverage for multi-gene assays. Hospital antimicrobial stewardship programs incorporate pharmacogenomic alerts into electronic medical records, creating consistent test pull-through. Pharmaceutical sponsors co-develop companion diagnostics to derisk new-drug launches, fueling demand for analytically validated pharmacogenomic panels.

Wider Integration Into Newborn and Carrier Screening Programs

Sequencing costs abated at a 14% annual clip between 2021 and 2024, prompting policymakers to re-evaluate newborn screening menus. The U.S. Recommended Uniform Screening Panel now lists 35 conditions, with SMA reaching full state adoption in 2.1 years. China’s multicenter NGS newborn pilot confirmed feasibility for monogenic disorders, while India’s National Biobank Consortium earmarked funds for expanded carrier screening infrastructure. Pilot data show that broad panels identify risk variants in nearly 10% of couples pursuing assisted reproduction. Pay-for-performance incentives allow regional labs to bundle postpartum pharmacogenomic screening, generating recurring revenue streams within the gene panel market.

Escalating Bioinformatics Workforce Shortage

Clinical labs confront a tight supply of accredited variant scientists as test complexity rises. Training pipelines lag behind job growth, with only 20 U.S. molecular genetics fellowship slots graduating annually. AI tools offset routine interpretation, but oversight roles still require certified professionals, creating bottlenecks in high-volume centers. African initiatives under H3Africa demonstrate similar gaps, prompting distance-learning programs for local researchers. Until broad upskilling closes the gap, turnaround-time gains from sequencing hardware will be capped, moderating expansion of the gene panel market.

Data Sovereignty and Cross-Border Transfer Restrictions

The European Health Data Space regulation permits secondary health-data use but demands explicit patient-level consent for cross-border transfers, raising compliance costs for multinational labs. Singapore’s Personal Data Protection Act imposes contractual clauses for genomic exports, while U.S. anti-China biotech bills tighten supply-chain scrutiny. These hurdles fragment global reference labs into regional silos, reducing dataset diversity and slowing AI model improvement. Consequently, test developers must stand-up in-country bioinformatics pipelines, inflating overhead and tempering the gene panel market’s scale benefits.

*Our forecasts treat driver/restraint impacts as directional, not additive. The impact forecasts reflect baseline growth, mix effects, and variable interactions.

Segment Analysis

By Products & Services: Testing Services Drive Market Evolution

Testing Services revenue is on track for a 16.55% CAGR through 2031, reflecting laboratories’ pivot from kit sales toward bundled sequencing-plus-interpretation offerings. The gene panel market size for Testing Services is projected to climb as reimbursement and clinician familiarity encourage send-out testing. Multi-gene oncology panels anchor referral volumes, enabling labs to amortize infrastructure and cross-sell pharmacogenomic screening.

Test Kits remain foundational, holding 64.72% revenue share in 2025 because hospitals still value in-house control over sample flows. Yet as CLIA-certified labs like Labcorp integrate Invitae’s oncology assets, they gain the scale to undercut hospital lab costs while guaranteeing 10-day turnaround for complex cases. Bioinformatics-only subscriptions—classified in the Others segment—grow as laboratories license AI pipelines such as QIAGEN QCI Interpret to process legacy FASTQ files, opening an asset-light entry path for regional players.

By Technique: Hybridization Capture Gains on Amplicon Dominance

Amplicon-based methods generated 61.55% of total revenue, underpinned by rapid PCR amplification workflows suited to FFPE tissue and liquid biopsy applications. Nevertheless, hybridization capture systems will deliver a 16.48% CAGR to 2031, increasing their contribution as laboratories prioritize even coverage over speed for comprehensive genomic profiling.

The gene panel market share held by amplicon platforms erodes gradually because hybrid capture demonstrates lower GC-bias and superior detection of copy-number variants in high-throughput oncology testing. Vendors like Roche and QIAGEN commercialize ready-to-run capture panels for circulating tumor DNA, allowing community labs to deploy liquid biopsy with minimal validation. Enzymatic DNA synthesis, while nascent, promises longer oligo length and greener chemistry, setting the stage for custom panel manufacturing at scale and further reshaping technique preferences.

By Application: Pharmacogenetics Accelerates Beyond Cancer Risk Assessment

Cancer Risk Assessment retained 48.12% revenue share in 2025 thanks to well-established hereditary cancer pathways and universal BRCA testing guidelines. Yet Pharmaco­genetics, is forecast to log the fastest 16.42% CAGR through 2031, lifting its share of the gene panel market size to nearly one-quarter. Hospital stewardship programs embed prescription alerts that automatically order pharmacogenomic panels before high-risk therapy initiation, normalizing routine testing.

Multi-gene drug-metabolism panels save payers treatment-failure costs, helping negotiate value-based reimbursement contracts. Congenital and rare-disease diagnosis advances in parallel, fueled by ultra-rapid whole-genome protocols that return results in 20 hours for NICU admissions. Population-scale preventive programs, from Vermont’s 431-gene voluntary adult screen to South Korea’s Welfare Genome pilot, demonstrate high participant uptake, broadening future test demand within the gene panel market.

By End User: Diagnostic Laboratories Outpace Hospital Growth

Hospitals and clinics generated 56.20% of spending in 2025, because embedded genetic counselors and on-site phlebotomy simplify testing logistics. Diagnostic laboratories, however, will compound at 16.29% annually through 2031 as they exploit scale economies across centralized sample intake, robotics, and AI interpretation pipelines.

Pharmaceutical and biotech companies raise demand for gene panels as companion diagnostics become prerequisites for market access. Agilent’s alliance with Incyte on hematology assays exemplifies co-development deals that lock specific panels into late-stage clinical trials. Research institutes leverage discounted panel pricing to sequence hundreds of thousands of samples for drug-target discovery, indirectly expanding the commercial installed base and cementing a service-oriented supply chain.

Geography Analysis

North America contributed 42.10% of global revenue in 2025, buoyed by CMS coverage under National Coverage Determination 90.2 and private-payer parity laws. U.S. reference labs roll out tumor-agnostic panels paired with real-time prescription decision support, capturing recurrent monitoring orders. Canada trials pan-province pharmacogenomic reimbursement frameworks to mitigate adverse drug events, while Mexico’s national genomics consortium negotiates cross-border sample logistics and shared variant databases.

Asia-Pacific is the fastest growing geography with a 16.58% CAGR to 2031. China’s newborn sequencing pilots span more than 20 provincial hospitals, demonstrating cost per sample under USD 150 by pooling barcoded libraries. India’s GenomeIndia project seeds regional testing hubs and incentivizes private labs to meet a projected 12-million sample backlog by 2030. South Korea’s Welfare Genome Project links lifestyle coaching apps to sequencing results, increasing test completion rates and post-test engagement. Meanwhile, Japan’s national insurance funds 2 comprehensive cancer panels per patient lifetime, though rural access disparities persist due to specialist concentration in metropolitan centers.

Europe posts steady adoption as the European Health Data Space clarifies secondary-use rights, albeit at the cost of stricter cross-border transfer compliance. Germany funnels de-identified genomic data into federally managed trusted research environments, catalyzing AI model training partnerships with health-tech start-ups. Switzerland mirrors Japanese reimbursement breadth but contends with patient-awareness gaps in non-urban cantons. Middle East and Africa remain latency markets; however, H3Africa builds local sequencing core facilities and distance-learning programs that nurture the talent base necessary for long-run gene panel market expansion.

Regulatory Landscape

Gene panel testing is governed by evolving in vitro diagnostics and clinical laboratory requirements that shape panel claims, reportable content, and evidence thresholds for reimbursement-aligned use. In the United States, CMS coverage for NGS in advanced cancer under National Coverage Determination (NCD) 90.2 continues to anchor payer pathways for oncology panels. In April 2026, the FDA added device-level clarity by classifying a setmelanotide eligibility gene variant detection system as a Class II device with special controls (21 CFR 862.1164), which reinforces expectations around analytical performance and labeling for targeted genetic tests.

Outside the US, requirements around companion diagnostics and genomic data handling add complexity to multinational gene-panel workflows. In the European Union, the In Vitro Diagnostic Regulation (IVDR) framework maintains EMA consultation requirements for companion diagnostics under Article 48, with transitional arrangements affecting how quickly legacy assays can be updated and re-certified. In China, oversight spans NMPA device review and human genetic resources controls for certain studies. In June 2026, NMPA-associated bodies (CDE/CMDE) issued guidance that includes technical review requirements for NGS-based tumor genetic variation detection reagents and reporting stratification, influencing panel design and the scope of variants laboratories can return to clinicians.

Market Opportunities and Future Outlook

Near-term whitespace is building in end-to-end workflows that deliver faster turnaround and reduce operational barriers for hospitals and decentralized labs, with particular traction in oncology profiling and MRD-adjacent longitudinal use cases. FDA actions and vendor roadmaps support this shift. In May 2026, Tempus received FDA approval for a tumor-only indication for its xT CDx NGS platform, allowing testing without matched normal samples and widening the patient and care settings that can operationalize comprehensive profiling. At the same time, kit and informatics vendors are packaging components to cut hands-on time and interpretation friction, including Integrated DNA Technologies (IDT) outlining an NGS innovation roadmap in February 2026 across library preparation and hybridization capture elements for cancer research workflows.

Guideline and payer criteria are also opening clearer pockets of demand for multigene panels, where medical-necessity documentation is more straightforward, which can support higher testing consistency and repeat ordering. Carelon Medical Benefits Management updated hereditary cancer testing guidelines in April 2026 (with additional 2026 updates referenced in the evidence pack). In May 2026, the Japanese Society for Hereditary Tumors issued multigene panel testing guidance. Together, these developments reinforce clinical criteria and use cases across germline risk assessment, prognosis support, and treatment optimization, and they favor suppliers that can bundle panel content, validated bioinformatics, and report-ready clinical interpretation while meeting data-sovereignty and cross-border transfer constraints through regionalized analytics and compliant data handling.